The research, led by Russian biologist Denis Rebrikov, has not led to the birth of gene-edited babies—yet.

The authors have requested a retraction of a paper that found people with the CCR5 Δ32 variant are more likely to die sooner.

Emails reveal that a facility in Dubai and others have asked geneticist He Jiankui for help in gene-editing embryos.

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

After the reported birth of CRISPRed babies in China, experts want to take time to consider the scientific, social, ethical, and philosophical consequences of editing heritable human DNA.

After the controversy of a Chinese scientist who was involved in editing the genomes of twin girls, the country puts forth tighter guidelines.

Two studies show signs that the introduced DNA is functioning, but it’s too early to know if patients actually benefit.

Multiple researchers were aware of He Jiankui’s clinical trial before the news became public in November.

2018 closed with hubbub surrounding the purported birth of babies whose genomes had been edited using CRISPR. What will 2019 hold for CRISPR’s use in humans?